腹膜癌新发病例的流行病学研究

腹膜癌是指在腹膜上发生和（或）发展的一类恶性肿瘤，包括原发性腹膜癌和继发性腹膜癌。既往认为腹膜癌是一种终末期疾病，无特殊治疗，患者生存期短，预后差。随着对腹膜癌认识的转变，肿瘤学界将其视为一种可治性区域癌转移，开创了以肿瘤细胞减灭术加腹腔热灌注化疗为核心的综合治疗技术体系，并以此建立了专业化腹膜癌诊疗中心，显著延长了患者生存，部分患者甚至能达到临床治愈。然而在中国，目前规范化腹膜癌诊疗中心少，但腹膜癌患者数量庞大，大部分患者得不到规范化治疗，导致生存和预后并不理想。本文旨在根据我国国家癌症中心发布的癌症新发病例统计数据，结合腹膜癌的临床预后资料，按照临床流行病学的研究方法，估算我国所需腹膜癌诊疗中心数，为推广我国腹膜癌规范化诊疗技术体系提供数据支撑，促进腹膜肿瘤学科发展。

Epidemiological Study of New Cases of Peritoneal Metastases

Peritoneal metastases (PM) are defined as the primary or secondary occurrence/progression of malignant tumor in peritoneum. PM were previously thought to be a terminal disease without effective treatment, with short survival and poor prognosis. With the change in the understanding of PM, the oncology communities regard it as a curable regional cancer metastasis, and create a comprehensive treatment technology system with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as the core, and establish professional PM treatment centers based on this. The professional PM treatment centers have significantly prolonged the survival of patients, and some patients can even achieve clinical cure. However, in China, there are very few professional PM treatment centers, but the number of PM patients is huge, and most of the patients can’t receive professional treatment, resulting in poor survival and prognosis. Based on the cancer statistics in 2015 published by China National Cancer Center Registry and clinical outcome literature on peritoneal metastasis, this paper uses clinical epidemiology methodology to calculate the number of newly diagnosed patients with peritoneal metastasis, to estimate the number of specialized peritoneal cancer centers required, to provide data support for the promotion of professional treatment technology system for PM in our country, and to boost the development of peritoneal oncology.